SCHEMBL6835209

SCHEMBL6835209

C[N+](C)(C)CCCCCC[N+](C)(C)C1CCN(c2ccc(N)cc2)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.37
GFER P55789 4/20 0.37
KDM4E B2RXH2 4/20 0.37
GAA P10253 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
RAD52 P43351 2/20 0.37
ALDH1A1 P00352 4/20 0.36
KMT2A Q03164 2/20 0.36
ADRA2C P18825 1/20 0.36
PTK2B Q14289 1/20 0.36
ESR2 Q92731 1/20 0.36
HTT P42858 2/20 0.34
THRB P10828 2/20 0.34
RECQL P46063 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
USP2 O75604 1/20 0.34
TP53 P04637 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2929100 0.96 MAPT (0.40) MAPTGFERKDM4EGAASMN1; SMN2
Hydrochloric Acid SCHEMBL6494082 0.95 MAPT (0.39) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL2929917 0.92 MAPT (0.41) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL2267999 0.91 GRM2 (0.43) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL2266681 0.91 GRM2 (0.43) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL2265915 0.91 GRM2 (0.43) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL2269575 0.91 GRM2 (0.43) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL2268631 0.91 GRM2 (0.43) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL2272222 0.91 GRM2 (0.43) MAPTGFERKDM4EGAASMN1; SMN2
Hydrochloric Acid SCHEMBL6493275 0.91 MAPT (0.40) MAPTGFERKDM4EGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040221400-A1 Dyeing composition comprising a cationic tertiary para-phenylenediamine and a monosaccharide or disaccharide, processes and uses L'OREAL (FR) 2004-11-11 US claimed
US-20040221400-A1 Dyeing composition comprising a cationic tertiary para-phenylenediamine and a monosaccharide or disaccharide, processes and uses L'OREAL (FR) 2004-11-11 US disclosed
US-20040220198-A1 Methods for treating malaria by modulation of G protein function NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040221400-A1 Dyeing composition comprising a cationic tertiary para-phenylenediamine and a monosaccharide or disaccharide, processes and uses KRT18, DPM1, DSG1 MAPT 1357/4885GFER 4300/4885KDM4E 3092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.